The Alliance for Regenerative Medicine Holds Fourth Annual Partnering Forum at the Meeting on the Mesa - October 7 and 8

-  Meeting will include plenary sessions on latest developments in both gene and cell therapy; UPenn’s Carl June, M.D. featured speaker at program’s Public Forum - 

WASHINGTON, DC, July 30, 2014 – The Alliance for Regenerative Medicine (ARM), the international organization representing the interests of the advanced therapies (cell therapy, gene therapy and tissue engineering) today announced that the fourth annual Partnering Forum will take place October 7 and 8, 2014 as part of the Stem Cell Meeting on the Mesa in La Jolla, California. This forum is the first and only partnering meeting organized specifically for the regenerative medicine and advanced therapies sectors. Each year the Partnering Forum assembles an extensive network of companies – including large pharma, investors, research institutes, government agencies and medical philanthropies seeking opportunities to expand key relationships in the field.

In addition to providing updates on recent advances in the industry, this year’s program will include two plenary sessions, one focused on cell therapy featuring top executives from leading companies in the space such as Mesoblast and Athersys in addition to large pharma and tools providers, Johnson & Johnson and Life Technologies. The second plenary session, featuring Sangamo BioSciences and bluebird bio, among others, will focus on gene and gene-modified cell therapies and explore how these cutting-edge technologies can be deployed into the healthcare system through a sustainable and cost-effective process.

The Partnering Forum will take place at the Estancia La Jolla Hotel & Spa, La Jolla, California. Following the close of the Partnering Forum on October 8 is a Public Forum and Reception held at the Sanford Consortium for Regenerative Medicine. This presentation, which is open to the general public and aimed at fostering relationships between industry and academia, will feature Carl June, M.D., Richard W. Vague Professor in Immunotherapy at the University of Pennsylvania. The Stem Cell Meeting on the Mesa’s ninth Annual Scientific Symposium will immediately follow on October 9 at the Salk Institute for Biological Studies. The Scientific Symposium, organized by the Sanford Consortium for Regenerative Medicine, is attended by leading scientists and researchers in the field, as well as participants from the business and patient advocacy communities. Combined, this three-day conference will attract nearly 800 attendees from around the globe, highlighting the promise and progress of this rapidly evolving, interdisciplinary field.

“Each year the Meeting on the Mesa has grown both in the number of participants and the caliber of presenters, and the conference has become an annual event for many of the leaders throughout the regenerative medicine and advanced therapies fields,” said Geoff MacKay, President and Chief Executive Officer of Organogenesis Inc. and Chairman of ARM. “This year the Partnering Forum has expanded to include an emphasis not only on cell therapies, but also gene and gene-modified cell therapy technologies. This, like the recent formation of ARM’s Gene Therapy Section, is a natural progression for the meeting as the advanced therapies sector expands.”

In addition to the more than 10 panels throughout the three-day program, 50 cutting-edge companies seeking partners and investors will also present during the Partnering Forum. More than 700 one-on-one meetings will also be scheduled using the EBD Group’s state-of-the-art partnering software. The Partnering Forum was developed by the Alliance for Regenerative Medicine (ARM) and the California Institute for Regenerative Medicine (CIRM) in 2011 and has grown its attendance by 70% over the past three years. Life Technologies Corporation, a Thermo Fisher Scientific Brand is the meeting’s founding and platinum-level sponsor.

To learn more or to register for the 2014 Stem Cell Meeting on the Mesa please visit Registration is complimentary for investors and credentialed members of the media.

About The Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, DC to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 175 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit